Therapeutic recombinant immune complexes (rICs) inhibit T cell recruitment to the spinal cord during Experimental Autoimmune Encephalomyelitis (EAE)

Abstract Multiple sclerosis (MS) is an autoimmune neurodegenerative disease mediated by autoreactive Th1 and Th17 cells that migrate into the central nervous system (CNS) target myelin proteins ultimately leading to neuronal damage. Current immunomodulatory treatments reduce severity but do not cure disease, they work for all patients. Recombinant ICs recapitulate anti-inflammatory properties of intravenous immunoglobulin may be a viable therapy MS. The objective our study was determine if rIC, M019, could inhibit T cell recruitment CNS using EAE model. To demonstrate M019 when given therapeutically, C57BL/6 mice were immunized with CFA-MOG 35–55emulsion followed pertussis toxin induce EAE. Upon symptom development, randomly assigned either vehicle or treatment groups treated daily. Mice exhibited reduced clinical scores lethality compared mice. Flow cytometric analysis infiltration revealed inhibited CD4 +and CD8 +T However, spleen from had similar levels increased group. These results suggest inhibiting responses in periphery their CNS. effect likely indirect, as vivo drug binding studies show binds strongly monocytes low level cells. Our effective therapeutic MS